Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(1.79) by 5.59 percent. This is a 9.03 percent decrease over losses of $(1.55) per share from the same period last year. The company reported quarterly sales of $20.746 million which beat the analyst consensus estimate of $13.646 million by 52.03 percent. This is a 137.75 percent increase over sales of $8.726 million the same period last year.